Does the media favor ABCL or BMRN?

In the previous week, BioMarin Pharmaceutical had 16 more articles in the media than AbCellera Biologics. MarketBeat recorded 18 mentions for BioMarin Pharmaceutical and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat BioMarin Pharmaceutical's score of 0.70 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 4 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or MDGL?

In the previous week, Madrigal Pharmaceuticals had 6 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat Madrigal Pharmaceuticals' score of 0.70 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or ABCL?

In the previous week, Halozyme Therapeutics had 19 more articles in the media than AbCellera Biologics. MarketBeat recorded 21 mentions for Halozyme Therapeutics and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat Halozyme Therapeutics' score of 0.89 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARWR or ABCL?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat Arrowhead Pharmaceuticals' score of 0.50 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABCL or KRYS?

In the previous week, Krystal Biotech had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 4 mentions for Krystal Biotech and 2 mentions for AbCellera Biologics. Krystal Biotech's average media sentiment score of 1.66 beat AbCellera Biologics' score of 0.94 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

AbCellera Biologics (ABCL) Competitors

$11.67 +0.26 (+2.28%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$11.89 +0.22 (+1.89%)

As of 07:01 AM Eastern

Compare

ABCL vs. BMRN, MDGL, HALO, ARWR, and KRYS

Should you buy AbCellera Biologics stock or one of its competitors? AbCellera Biologics's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Arrowhead Pharmaceuticals (ARWR), and Krystal Biotech (KRYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AbCellera Biologics compare to BioMarin Pharmaceutical?

AbCellera Biologics (NASDAQ:ABCL) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AbCellera Biologics has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to AbCellera Biologics' net margin of -248.83%. BioMarin Pharmaceutical's return on equity of 5.32% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	47.63	-$146.41M	-$0.54	N/A
BioMarin Pharmaceutical	$3.22B	3.89	$348.90M	$0.37	174.95

AbCellera Biologics currently has a consensus price target of $12.83, indicating a potential upside of 9.97%. BioMarin Pharmaceutical has a consensus price target of $89.17, indicating a potential upside of 37.76%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

In the previous week, BioMarin Pharmaceutical had 16 more articles in the media than AbCellera Biologics. MarketBeat recorded 18 mentions for BioMarin Pharmaceutical and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat BioMarin Pharmaceutical's score of 0.70 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	4 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats AbCellera Biologics on 11 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Madrigal Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Madrigal Pharmaceuticals had 6 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat Madrigal Pharmaceuticals' score of 0.70 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	47.63	-$146.41M	-$0.54	N/A
Madrigal Pharmaceuticals	$958.40M	12.75	-$288.28M	-$12.89	N/A

Madrigal Pharmaceuticals has a net margin of -25.32% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

AbCellera Biologics has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AbCellera Biologics presently has a consensus target price of $12.83, suggesting a potential upside of 9.97%. Madrigal Pharmaceuticals has a consensus target price of $699.64, suggesting a potential upside of 32.24%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

AbCellera Biologics beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Halozyme Therapeutics has a net margin of 24.86% compared to AbCellera Biologics' net margin of -248.83%. Halozyme Therapeutics' return on equity of 260.98% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.81	$316.89M	$3.35	32.37
AbCellera Biologics	$75.13M	47.63	-$146.41M	-$0.54	N/A

In the previous week, Halozyme Therapeutics had 19 more articles in the media than AbCellera Biologics. MarketBeat recorded 21 mentions for Halozyme Therapeutics and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat Halozyme Therapeutics' score of 0.89 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Halozyme Therapeutics currently has a consensus price target of $91.20, indicating a potential downside of 15.90%. AbCellera Biologics has a consensus price target of $12.83, indicating a potential upside of 9.97%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Halozyme Therapeutics beats AbCellera Biologics on 10 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.94 beat Arrowhead Pharmaceuticals' score of 0.50 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	11.17	-$1.63M	-$2.25	N/A
AbCellera Biologics	$75.13M	47.63	-$146.41M	-$0.54	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Arrowhead Pharmaceuticals presently has a consensus target price of $99.15, indicating a potential upside of 50.71%. AbCellera Biologics has a consensus target price of $12.83, indicating a potential upside of 9.97%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AbCellera Biologics beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Krystal Biotech?

AbCellera Biologics (NASDAQ:ABCL) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

AbCellera Biologics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to AbCellera Biologics' net margin of -248.83%. Krystal Biotech's return on equity of 19.34% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Krystal Biotech	54.82%	19.34%	17.65%

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AbCellera Biologics presently has a consensus target price of $12.83, suggesting a potential upside of 9.97%. Krystal Biotech has a consensus target price of $365.40, suggesting a potential upside of 8.53%. Given AbCellera Biologics' higher possible upside, research analysts clearly believe AbCellera Biologics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Krystal Biotech has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	47.63	-$146.41M	-$0.54	N/A
Krystal Biotech	$389.13M	25.61	$204.83M	$7.98	42.19

In the previous week, Krystal Biotech had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 4 mentions for Krystal Biotech and 2 mentions for AbCellera Biologics. Krystal Biotech's average media sentiment score of 1.66 beat AbCellera Biologics' score of 0.94 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Krystal Biotech beats AbCellera Biologics on 12 of the 16 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.50B	$3.85B	$7.23B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-21.61	14.33	273.89	25.33
Price / Sales	47.63	1,398.16	639.64	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	3.61	15.13	10.33	6.24
Net Income	-$146.41M	-$22.78M	$3.49B	$358.55M
7 Day Performance	11.57%	-2.50%	-0.80%	-1.20%
1 Month Performance	4.20%	-2.84%	-1.33%	-4.26%
1 Year Performance	155.36%	37.93%	21.15%	5.47%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	2.0718 of 5 stars	$11.67 +2.3%	$12.83 +10.0%	+144.7%	$3.50B	$75.13M	N/A	562	Positive News
BMRN BioMarin Pharmaceutical	4.603 of 5 stars	$65.54 +0.0%	$89.17 +36.1%	+20.0%	$12.69B	$3.22B	177.11	3,221	Analyst Forecast
MDGL Madrigal Pharmaceuticals	3.2699 of 5 stars	$535.06 +0.4%	$699.64 +30.8%	+23.9%	$12.36B	$958.40M	N/A	915
HALO Halozyme Therapeutics	3.1505 of 5 stars	$107.42 +0.4%	$91.20 -15.1%	+43.0%	$12.19B	$1.40B	32.07	423
ARWR Arrowhead Pharmaceuticals	2.8227 of 5 stars	$84.60 +2.2%	$99.15 +17.2%	+123.6%	$11.93B	$829.45M	N/A	711	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. BMRN, MDGL, HALO, ARWR, and KRYS

How does AbCellera Biologics compare to BioMarin Pharmaceutical?

Summary

How does AbCellera Biologics compare to Madrigal Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Halozyme Therapeutics?

Summary

How does AbCellera Biologics compare to Arrowhead Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. BMRN, MDGL, HALO, ARWR, and KRYS

How does AbCellera Biologics compare to BioMarin Pharmaceutical?

Do insiders & institutionals have more ownership in ABCL or BMRN?

Which has more risk & volatility, ABCL or BMRN?

Is ABCL or BMRN more profitable?

Which has preferable earnings & valuation, ABCL or BMRN?

Do analysts rate ABCL or BMRN?

Does the media favor ABCL or BMRN?

Summary

How does AbCellera Biologics compare to Madrigal Pharmaceuticals?

Does the media refer more to ABCL or MDGL?

Which has preferable valuation & earnings, ABCL or MDGL?

Is ABCL or MDGL more profitable?

Which has more risk & volatility, ABCL or MDGL?

Do institutionals & insiders hold more shares of ABCL or MDGL?

Do analysts prefer ABCL or MDGL?

Summary

How does AbCellera Biologics compare to Halozyme Therapeutics?

Is HALO or ABCL more profitable?

Which has more risk & volatility, HALO or ABCL?

Which has better valuation and earnings, HALO or ABCL?

Does the media prefer HALO or ABCL?

Do insiders and institutionals have more ownership in HALO or ABCL?

Do analysts recommend HALO or ABCL?

Summary

How does AbCellera Biologics compare to Arrowhead Pharmaceuticals?

Which has more volatility and risk, ARWR or ABCL?

Does the media prefer ARWR or ABCL?

Do institutionals and insiders have more ownership in ARWR or ABCL?

Which has preferable valuation & earnings, ARWR or ABCL?

Is ARWR or ABCL more profitable?

Do analysts recommend ARWR or ABCL?

Summary

How does AbCellera Biologics compare to Krystal Biotech?

Which has more volatility and risk, ABCL or KRYS?

Is ABCL or KRYS more profitable?

Do insiders & institutionals have more ownership in ABCL or KRYS?

Do analysts rate ABCL or KRYS?

Which has preferable earnings and valuation, ABCL or KRYS?

Does the media favor ABCL or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools